DOCSLIB.ORG

Dissertation / Doctoral Thesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dissertation / Doctoral Thesis DISSERTATION / DOCTORAL THESIS Titel der Dissertation / Title of the Doctoral Thesis “In-depth mass spectrometry-based proteome profiling of inflammation-related processes” verfasst von / submitted by Andrea Bileck, MSc angestrebter akademischer Grad / in partial fulfilment of the requirements for the degree of Doktorin der Naturwissenschaften (Dr.rer.nat.) Doctor of Sciences (Dr.rer.nat.) Wien, 2016 / Vienna 2016 Studienkennzahl lt. Studienblatt / degree programme code as it appears on the student A 796 605 419 record sheet: Dissertationsgebiet lt. Studienblatt / Chemie / Chemistry field of study as it appears on the student record sheet: Betreut von / Supervisor: Univ. Prof. Dr. Christopher Gerner II This doctoral thesis is based on the following publications and manuscripts: Comprehensive assessment of proteins regulated by dexamethasone reveals novel effects in primary human peripheral blood mononuclear cells Andrea Bileck, Dominique Kreutz, Besnik Muqaku, Astrid Slany, Christopher Gerner Journal of Proteome Research, 2014, 13, (12), 5989-6000 Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage Andrea Bileck, Franziska Ferk, Halh Al-Serori, Verena J. Koller, Besnik Muqaku, Alexander Haslberger, Volker Auwärter, Christopher Gerner, Siegfried Knasmüller Archives of Toxicology, 2015, doi:10.1007/s00204-015-1569-7 Shotgun proteomics of primary human cells enables the analysis of signaling pathways and nuclear translocations related to inflammation Andrea Bileck, Rupert L. Mayer, Dominique Kreutz, Tamara Weiss, Astrid Slany, Christopher Gerner Journal of Proteome Research, 2015, manuscript under revision Contribution of human fibroblasts and endothelial cells to the hallmarks of inflammation as determined by proteome profiling Astrid Slany, Andrea Bileck, Dominique Kreutz, Rupert L. Mayer, Besnik Muqaku, Christopher Gerner Molecular & Cellular Proteomics, 2016, manuscript in press III IV Acknowledgements First and foremost, I want to express my sincere gratitude to my supervisor Univ.-Prof. Dr. Christopher Gerner. I especially want to thank him for giving me the great opportunity to perform my doctorate in his group as well as for his guidance, valuable support and for a lot of fruitful and inspiring discussions during this time. His tremendous enthusiasm and immense knowledge really motivated me to give my best and to learn something new every single day. I would like to give my sincere thanks to Dr. Astrid Slany helping and supporting me in every stage of my doctorate. I especially want to thank her for always willing to listen to me, her valuable advice and loyalty. Furthermore, I would like to thank my colleagues, which have become really good friends, Rupert Mayer, MSc, Mag. Dominique Kreutz and Mag. Günter Walder for their great support, advice and all the fun we had in the last years. I want to express my sincere gratitude also to Dr. Samuel Meier. I especially want to thank him for his tremendous support in the final phase of my doctorate. In addition, I want to thank all the other members of our working group, Ammar Tahir, MSc, Besnik Muqaku, MSc, Mag. Denise Wolrab, Peter Frühauf and Dr. Johanna Mader for their support, great discussions and the good working atmosphere. I would also like to express my gratitude to my former colleagues Dr. Michael Grössl and Editha Bayer for introducing me in the field of mass spectrometry and sample preparation, as well as to our diploma students, especially Raphael Ambros for their help and assistance. Last but not least, I want to thank my whole family and friends, especially my mother Herta Bileck, for their invaluable support, motivation, understanding and patience on every day of my life. V VI Table of Contents 1. Abbreviations ............................................................................................................... p. IX 2. Introduction ................................................................................................................. p. 1 2.1. Immune System and Inflammation ........................................................................... p. 1 2.2. Chronic Inflammation and Cancer ........................................................................... p. 4 2.3. Therapeutic Modulation of Inflammation ................................................................ p. 7 2.4. Mass Spectrometry-based Proteomics ...................................................................... p. 9 2.4.1. General Overview of Mass Spectrometry-based Proteomics .............................. p. 9 2.4.2. Gel-based Proteomics .......................................................................................... p. 10 2.4.3. Gel-free Proteomics ............................................................................................. p. 11 2.4.4. Ionization Sources in Mass Spectrometry-based Proteomics .............................. p. 11 2.4.5. Mass Analyzers Commonly Used in the Field of Proteomics ............................. p. 12 2.4.6. Ion Activation Methods in Mass Spectrometry-based Proteomics ..................... p. 14 2.5. General Overview of Applied Methods in this Doctoral Thesis .............................. p. 15 2.5.1. Isolation and Treatment of PBMCs ..................................................................... p. 15 2.5.2. Subcellular Fractionation ..................................................................................... p. 16 2.5.3. Sample Preparation for Mass Spectrometric Analysis ........................................ p. 16 2.5.4. LC-MS/MS Analysis ........................................................................................... p. 17 2.6. Challenge of Secretome Analysis ............................................................................. p. 18 2.7. High Data Density Obtained by Mass Spectrometry-based Proteomics .................. p. 20 2.8. Challenges in the Analysis of PTMs using Mass Spectrometry ............................... p. 22 2.9. Peptide Identification and False Discovery Rate Estimation ................................... p. 23 2.10. Research Justification ............................................................................................... p. 24 2.11. References ................................................................................................................ p. 29 3. Results and Discussion ................................................................................................ p. 33 3.1. Comprehensive Assessment of Proteins Regulated by Dexamethasone Reveals Novel Effects in Primary Human Peripheral Blood Mononuclear Cells .................. p. 33 3.2. Impact of a Synthetic Cannabinoid (CP-47,497-C8) on Protein Expression in Human Cells: Evidence for Induction of Inflammation and DNA Damage ............. p. 47 3.3. Shotgun Proteomics of Primary Human Cells Enables the Analysis of Signaling Pathways and Nuclear Translocations Related to Inflammation .............................. p. 63 3.4. Contribution of Human Fibroblasts and Endothelial Cells to the Hallmarks of Inflammation as Determined by Proteome Profiling ................................................ p. 97 4. Conclusions................................................................................................................... p. 143 5. Abstract ........................................................................................................................ p. 145 6. Zusammenfassung (German Abstract) ..................................................................... p. 146 7. Scientific Contributions ............................................................................................. p. 147 7.1. List of Publications ................................................................................................... p. 147 7.2. List of Oral Contributions ........................................................................................ p. 148 7.3. List of Poster Contributions ...................................................................................... p. 148 VII VIII 1. Abbreviations 2D-DIGE, 2-dimensional difference gel electrophoresis; 2D-PAGE, 2-dimensional polyacrylamide gel electrophoresis; ACN, acetonitrile; AP-1, transcription factor AP-1; APCs, antigen-presenting cells; BM, basement membrane; CID, collisional-induced fragmentation; COX, cyclooxygenase; CTLs, cytotoxic T cells; DAMP, damage-associated molecular pattern; DCs, dendritic cells; DTT, dithiothreitol; ECs, endothelial cells; EI, electron ionization; ESI, electrospray ionization; ETD, electron transfer dissociation; FA, formic acid; FASP, filter-aided sample preparation; FCS, fetal calf serum; FDR, false discovery rate; GC, glucocorticoid; GRE, glucocorticoid response element; HCD, higher energy collisional dissociation; HIF1α, hypoxia-inducible factor 1α; IAA, iodoacetamide; ICAM-1, intracellular adhesion molecule-1; IL, interleukin; IPGs, immobilized pH gradients; LC, liquid chromatography; LOX, lipoxygenase; LPS, lipopolysaccharide; MALDI-TOF, matrix-assisted laser/desorption ionization-time of flight; MMPs, matrix metalloproteinases; MRM, multiple reaction monitoring; MS, mass spectrometry; MWCO, molecular weight cut-off; NF-κB, nuclear factor- κB; NK cells, natural killer cells; NSAIDs, non-steroidal antiphlogistic drugs; PAMP, pathogen- associated molecular pattern; PBMCs, peripheral blood mononuclear cells; PG, prostaglandin; PHA, phytoheamagglutinin; PMF, peptide
Load more

Recommended publications
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • A Systematic Review on the Implications of O-Linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis
    cells Review A Systematic Review on the Implications of O-linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis 1, 1, 1 1,2,3, Rohitesh Gupta y, Frank Leon y, Sanchita Rauth , Surinder K. Batra * and Moorthy P. Ponnusamy 1,2,* 1 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68105, USA; [email protected] (R.G.); [email protected] (F.L.); [email protected] (S.R.) 2 Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 681980-5900, USA 3 Department of Pathology and Microbiology, UNMC, Omaha, NE 68198-5900, USA * Correspondence: [email protected] (S.K.B.); [email protected] (M.P.P.); Tel.: +402-559-5455 (S.K.B.); +402-559-1170 (M.P.P.); Fax: +402-559-6650 (S.K.B. & M.P.P.) Equal contribution. y Received: 21 January 2020; Accepted: 12 February 2020; Published: 14 February 2020 Abstract: Glycosylation is the most commonly occurring post-translational modifications, and is believed to modify over 50% of all proteins. The process of glycan modification is directed by different glycosyltransferases, depending on the cell in which it is expressed. These small carbohydrate molecules consist of multiple glycan families that facilitate cell–cell interactions, protein interactions, and downstream signaling. An alteration of several types of O-glycan core structures have been implicated in multiple cancers, largely due to differential glycosyltransferase expression or activity. Consequently, aberrant O-linked glycosylation has been extensively demonstrated to affect biological function and protein integrity that directly result in cancer growth and progression of several diseases.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • C1GALT1 in Health and Disease (Review)
    ONCOLOGY LETTERS 22: 589, 2021 C1GALT1 in health and disease (Review) XIAOJIE SUN1, MENGRU ZHAN2, XUN SUN3, WANQI LIU1 and XIANGWEI MENG1 Departments of 1Gastroenterology, 2Hepatobiliary and Pancreatic Medicine, and 3Pathology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China Received March 18, 2021; Accepted May 18, 2021 DOI: 10.3892/ol.2021.12850 Abstract. O‑linked glycosylation (O‑glycosylation) and and human diseases. Since the mechanism and regulation of N‑linked glycosylation (N‑glycosylation) are the two most C1GALT1 and O‑glycosylation remain elusive, further studies important forms of protein glycosylation, which is an are required to elucidate their effects on development and important post‑translational modification. The regulation disease. of protein function involves numerous mechanisms, among which protein glycosylation is one of the most important. Core 1 synthase glycoprotein‑N‑acetylgalactosamine Contents 3‑β‑galactosyltransferase 1 (C1GALT1) serves an important role in the regulation of O‑glycosylation and is an essential 1. Introduction enzyme for synthesizing the core 1 structure of mucin‑type 2. C1GALT1 in normal development and non‑neoplastic O‑glycans. Furthermore, C1GALT1 serves a vital role in a diseases number of biological functions, such as angiogenesis, platelet 3. C1GALT1 as an oncogene production and kidney development. Impaired C1GALT1 4. C1GALT1 as a tumor suppressor expression activity has been associated with different types of 5. Cosmc and integrin β1 human diseases, including inflammatory or immune‑mediated 6. Itraconazole, an inhibitor of C1GALT1 diseases, and cancer. O‑glycosylation exists in normal tissues, 7. Conclusion as well as in tumor tissues. Previous studies have revealed that changes in the level of glycosyltransferase in different types of 1.
    [Show full text]
  • C1GALT1 Enhances Proliferation of Hepatocellular Carcinoma Cells Via Modulating MET Glycosylation and Dimerization
    Published OnlineFirst July 5, 2013; DOI: 10.1158/0008-5472.CAN-13-0869 Cancer Tumor and Stem Cell Biology Research C1GALT1 Enhances Proliferation of Hepatocellular Carcinoma Cells via Modulating MET Glycosylation and Dimerization Yao-Ming Wu1,3, Chiung-Hui Liu2, Miao-Juei Huang2,3, Hong-Shiee Lai1, Po-Huang Lee1, Rey-Heng Hu1, and Min-Chuan Huang2,3 Abstract Altered glycosylation is a hallmark of cancer. The core 1 b1,3-galactosyltransferase (C1GALT1) controls the formation of mucin-type O-glycans, far overlooked and underestimated in cancer. Here, we report that C1GALT1 mRNA and protein are frequently overexpressed in hepatocellular carcinoma tumors compared with nontumor liver tissues, where it correlates with advanced tumor stage, metastasis, and poor survival. Enforced expression of C1GALT1 was sufficient to enhance cell proliferation, whereas RNA interference– mediated silencing of C1GALT1 was sufficient to suppress cell proliferation in vitro and in vivo.Notably, C1GALT1 attenuation also suppressed hepatocyte growth factor (HGF)–mediated phosphorylation of the MET kinase in hepatocellular carcinoma cells, whereas enforced expression of C1GALT1 enhanced MET phosphorylation. MET blockade with PHA665752 inhibited C1GALT1-enhanced cell viability. In support of these results, we found that the expression level of phospho-MET and C1GALT1 were associated in primary hepatocellular carcinoma tissues. Mechanistic investigations showed that MET was decorated with O-glycans, as revealed by binding to Vicia villosa agglutinin and peanut agglutinin. Moreover, C1GALT1 modified the O-glycosylation of MET, enhancing its HGF-induced dimerization and activation. Together, our results indicate that C1GALT1 overexpression in hepatocellular carcinoma activates HGF signaling via modulation of MET O-glycosylation and dimerization, providing new insights into how O-glycosylation drives hepatocellular carcinoma pathogenesis.
    [Show full text]
  • Multiplexed Surrogate Analysis of Glycotransferase Activity in Whole Biospecimens † † ‡ Chad R
    Article pubs.acs.org/ac Multiplexed Surrogate Analysis of Glycotransferase Activity in Whole Biospecimens † † ‡ Chad R. Borges, ,* Douglas S. Rehder, and Paolo Boffetta † Molecular Biomarkers Unit, The Biodesign Institute at Arizona State University, Tempe, Arizona 85287, United States ‡ Institute for Translational Epidemiology and Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York 10029, United States *S Supporting Information ABSTRACT: Dysregulated glycotransferase enzymes in can- cer cells produce aberrant glycanssome of which can help facilitate metastases. Within a cell, individual glycotransferases promiscuously help to construct dozens of unique glycan structures, making it difficult to comprehensively track their activity in biospecimensespecially where they are absent or inactive. Here, we describe an approach to deconstruct glycans in whole biospecimens then analytically pool together resulting monosaccharide-and-linkage-specific degradation products (“glycan nodes”) that directly represent the activities of specific glycotransferases. To implement this concept, a reproducible, relative quantitation-based glycan methylation analysis methodology was developed that simultaneously captures information from N-, O-, and lipid linked glycans and is compatible with whole biofluids and homogenized tissues; in total, over 30 different glycan nodes are detectable per gas chromatography−mass spectrometry (GC-MS) run. Numerous nonliver organ cancers are known to induce the production of abnormally glycosylated serum proteins. Thus, following analytical validation, in blood plasma, the technique was applied to a group of 59 lung cancer patient plasma samples and age/gender/ smoking-status-matched non-neoplastic controls from the Lung Cancer in Central and Eastern Europe (CEE) study to gauge the clinical utility of the approach toward the detection of lung cancer.
    [Show full text]
  • MUC1 Is an Oncoprotein with a Significant Role in Apoptosis (Review)
    INTERNATIONAL JOURNAL OF ONCOLOGY 59: 68, 2021 MUC1 is an oncoprotein with a significant role in apoptosis (Review) KATARZYNA SUPRUNIUK and IWONA RADZIEJEWSKA Department of Medical Chemistry, Medical University of Białystok, 15‑222 Białystok, Poland Received April 19, 2021; Accepted June 29, 2021 DOI: 10.3892/ijo.2021.5248 Abstract. Mucin 1 (MUC1) is a membrane‑bound, highly Contents glycosylated protein that is overexpressed in all stages of malignant transformation. Overexpression of MUC1 together 1. Introduction with loss of polarization and hypoglycosylation are associ‑ 2. Apoptosis ated with resistance to apoptosis, which is the process that 3. MUC1 as a cancer‑associated membrane‑bound molecule results in efficient removal of damaged cells. Inhibition of the 4. Role of MUC1 in apoptosis apoptotic process is responsible for tumor development, tumor 5. Conclusions progression and drug resistance. MUC1 is considered as an oncogenic molecule that is involved in various signaling path‑ ways responsible for the regulation of apoptosis. Based on this, 1. Introduction the aim of the present study was to discuss the involvement of MUC1 in the divergent mechanisms regulating programmed The epithelium is a layer of cells that separates an organism from cell death. the external environment; it is coated by mucous gel, which is mainly composed of mucins (MUCs). MUCs are high‑molec‑ ular‑weight O‑linked glycoproteins synthesized by goblet cells. The human MUC family contains 22 characterized members (MUC1 to MUC22), which are divided into secreted and trans‑ membrane glycoproteins (1,2). Secreted gel‑forming MUCs, without a transmembrane domain, include MUC2, MUC5AC, Correspondence to: Dr Iwona Radziejewska, Department of MUC5B, MUC6, MUC7, MUC8 and MUC9.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Deep Evolutionary Analysis Reveals the Design Principles of Fold A
    RESEARCH ARTICLE Deep evolutionary analysis reveals the design principles of fold A glycosyltransferases Rahil Taujale1,2, Aarya Venkat3, Liang-Chin Huang1, Zhongliang Zhou4, Wayland Yeung1, Khaled M Rasheed4, Sheng Li4, Arthur S Edison1,2,3, Kelley W Moremen2,3, Natarajan Kannan1,3* 1Institute of Bioinformatics, University of Georgia, Athens, Georgia; 2Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia; 3Department of Biochemistry and Molecular Biology, University of Georgia, Athens, Georgia; 4Department of Computer Science, University of Georgia, Athens, Georgia Abstract Glycosyltransferases (GTs) are prevalent across the tree of life and regulate nearly all aspects of cellular functions. The evolutionary basis for their complex and diverse modes of catalytic functions remain enigmatic. Here, based on deep mining of over half million GT-A fold sequences, we define a minimal core component shared among functionally diverse enzymes. We find that variations in the common core and emergence of hypervariable loops extending from the core contributed to GT-A diversity. We provide a phylogenetic framework relating diverse GT-A fold families for the first time and show that inverting and retaining mechanisms emerged multiple times independently during evolution. Using evolutionary information encoded in primary sequences, we trained a machine learning classifier to predict donor specificity with nearly 90% accuracy and deployed it for the annotation of understudied GTs. Our studies provide an evolutionary framework for investigating complex relationships connecting GT-A fold sequence, structure, function and regulation. *For correspondence: [email protected] Introduction Competing interests: The Complex carbohydrates make up a large bulk of the biomass of any living cell and play essential authors declare that no roles in biological processes ranging from cellular interactions, pathogenesis, immunity, quality con- competing interests exist.
    [Show full text]
  • Supplemental Figures 04 12 2017
    Jung et al. 1 SUPPLEMENTAL FIGURES 2 3 Supplemental Figure 1. Clinical relevance of natural product methyltransferases (NPMTs) in brain disorders. (A) 4 Table summarizing characteristics of 11 NPMTs using data derived from the TCGA GBM and Rembrandt datasets for 5 relative expression levels and survival. In addition, published studies of the 11 NPMTs are summarized. (B) The 1 Jung et al. 6 expression levels of 10 NPMTs in glioblastoma versus non‐tumor brain are displayed in a heatmap, ranked by 7 significance and expression levels. *, p<0.05; **, p<0.01; ***, p<0.001. 8 2 Jung et al. 9 10 Supplemental Figure 2. Anatomical distribution of methyltransferase and metabolic signatures within 11 glioblastomas. The Ivy GAP dataset was downloaded and interrogated by histological structure for NNMT, NAMPT, 12 DNMT mRNA expression and selected gene expression signatures. The results are displayed on a heatmap. The 13 sample size of each histological region as indicated on the figure. 14 3 Jung et al. 15 16 Supplemental Figure 3. Altered expression of nicotinamide and nicotinate metabolism‐related enzymes in 17 glioblastoma. (A) Heatmap (fold change of expression) of whole 25 enzymes in the KEGG nicotinate and 18 nicotinamide metabolism gene set were analyzed in indicated glioblastoma expression datasets with Oncomine. 4 Jung et al. 19 Color bar intensity indicates percentile of fold change in glioblastoma relative to normal brain. (B) Nicotinamide and 20 nicotinate and methionine salvage pathways are displayed with the relative expression levels in glioblastoma 21 specimens in the TCGA GBM dataset indicated. 22 5 Jung et al. 23 24 Supplementary Figure 4.
    [Show full text]
  • Fibrosis Accumulation in Idiopathic
    Downloaded from http://www.jimmunol.org/ by guest on September 26, 2021 D. is online at: average * The Journal of Immunology published online 1 June 2011 from submission to initial decision 4 weeks from acceptance to publication Groshong, Gregory P. Cosgrove, Elizabeth F. Redente, Alison Bamberg, Kevin K. Brown, Nichole Reisdorph, Rebecca C. Keith, Stephen K. Frankel and David W. H. Riches http://www.jimmunol.org/content/early/2011/05/29/jimmun ol.1100447 Increased Cell Surface Fas Expression Is Necessary and Sufficient To Sensitize Lung Fibroblasts to Fas Ligation-Induced Apoptosis: Implications for Fibroblast Accumulation in Idiopathic Pulmonary Fibrosis Murry W. Wynes, Benjamin L. Edelman, Amanda G. Kostyk, Michael G. Edwards, Christopher Coldren, Steve J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2011/06/01/jimmunol.110044 7.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 26, 2021. Published June 1, 2011, doi:10.4049/jimmunol.1100447 The Journal of Immunology Increased Cell Surface Fas Expression Is Necessary and Sufficient To Sensitize Lung Fibroblasts to Fas Ligation-Induced Apoptosis: Implications for Fibroblast Accumulation in Idiopathic Pulmonary Fibrosis Murry W.
    [Show full text]